Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection

AIDS

Volumn 20, Issue 3, 2006, Pages 345-351

  Graham, Camilla S ^a,f   Wells, Annalee ^a   Liu, Tun ^b   Sherman, Kenneth E ^c   Peters, Marion ^d   Chung, Raymond T ^e   Bhan, Atul K ^e   Andersen, Janet ^b   Koziel, Margaret James ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

Cellular immunity; Hepatitis C virus; Interferon ; Interferon gamma; Interleukin 10

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; INTERLEUKIN 10; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5; PEGINTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ADOLESCENT; ADULT; ARTICLE; CANDIDA; CELLULAR IMMUNITY; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; OPEN STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; VIROLOGY;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DISEASE-FREE SURVIVAL; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; INTERFERON ALFA-2A; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 33645039071     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000206500.16783.2e     Document Type: Article

References (25)

1. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34:831-837.
2. Soriano V, Garcia-Samaniego J, Valencia E, Rodriguez-Rosado R, Munoz F, Gonzalez-Lahoz J. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 1999; 15:1-4.
3. Gebo KA, Diener-West M, Moore RD. Hospitalization rates differ by hepatitis C satus in an urban HIV cohort. J Acquir Immune Defic Syndr 2003; 34:165-173.
4. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32:492-497.
5. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated Interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292:2839-2848.
6. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-459.
7. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-450.
8. Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology 2002; 123:1070-1083.
9. Cramp ME, Carucci P, Rossol S, Chokshi S, Maertens G, Williams R, et al. Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia. Gut 1999; 44:424-429.
10. Leroux-Roels G, Esquivel CA, DeLeys R, Stuyver L, Elewaut A, Philippe J, et al. Lymphoproliferative responses to hepatitis C virus core, E1, E2, and NS3 in patients with chronic hepatitis C infection treated with interferon alfa. Hepatology 1996; 23:8-16.
11. Lohr HF, Gerken G, Roth M, Weyer S, Schlaak JF, Meyer zum Buschenfelde KH. The cellular immune responses induced in the follow-up of interferon- alpha treated patients with chronic hepatitis C may determine the therapy outcome. J Hepatol 1998; 29:524-532.
12. Missale G, Cariani E, Lamonaca V, Ravaggi A, Rossini A, Bertoni R, et al. Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b- and genotype 2c-infected patients. Hepatology 1997; 26:792-797.
13. Barnes E, Harcourt G, Brown D, Lucas M, Phillips R, Dusheiko G, et al. The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology 2002; 36:743-754.
14. Alatrakchi N, Di Martino V, Thibault V, Autran B. Strong CD4 Th1 responses to HIV and hepatitis C virus in HIV-infected long-term non-progressors co-infected with hepatitis C virus. AIDS 2002; 16:713-717.
15. Graham CS, Wells A, Liu T, Sherman KE, Peters M, Chung RT, et al. Antigen-specific immune responses and liver histology in HIV and hepatitis C coinfection. AIDS 2005; 19:767-773.
16. Lauer GM, Nguyen TN, Day CL, Robbins GK, Flynn T, McGowan K, et al. Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses. J Virol 2002; 76:2817-2826.
17. Valdez H, Anthony D, Farukhi F, Patki A, Salkowitz J, Heeger P, et al. Immune responses to hepatitis C and non-hepatitis C antigens in hepatitis C virus infected and HIV-1 coinfected patients. AIDS 2000; 14:2239-2246.
18. Valdez H, Carlson NL, Post AB, Asaad R, Heeger PS, Lederman MM, et al. HIV long-term non-progressors maintain brisk CD8 T cell responses to other viral antigens. AIDS 2002; 16:1113-1118.
19. Graham CS, Curry M, He Q, Afdhal N, Nunes D, Fleming C, et al. Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV. Hepatology 2004; 40:125-132.
20. Breiman L FJ, Olshen RA, Stone JC. Classification and regression trees. Belmont, CA: Wadsworth Publishing Company, Inc.; 1984.
21. Legrand E, Neau D, Galperine T, Trimoulet P, Moreau JF, Pitard V, et al. CD4 T lymphocyte proliferative responses to hepatitis C virus (HCV) antigens in patients coinfected with HCV and human immunodeficiency virus who responded to anti-HCV treatment. J Infect Dis 2002; 186:302-311.
22. Alatrakchi N, Di Martino V, Thibault V, Benhamou Y, Katlama C, Poynard T, et al. Decreased frequencies of virus-specific T helper type 1 cells during interferon alpha plus ribavirin treatment in HIV-hepatitis C virus co-infection. AIDS 2004; 18:121-123.
23. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
24. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
25. O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med 2004; 10:801-805.